Opti B i otix Health plc
( "Opti Bi o t ix" or "the Co m pan y")
OptiBi otix Health p lc (AI M : OPTI), a life sciences busi ness d e vel o ping products to tack le o besit y, high choleste r ol and diabetes, announces that Stephen O'Hara, CEO of Optibiotix, will be presenting at an investor evening hosted by Turner Pope Investments Ltd ("TPI"). The event will be held on Tuesday 19 September 2017 in Mayfair, London and will commence at 5pm.
To register your interest and obtain further details, please contact TPI on [email protected] or call 020 3621 4121.
No new material or trading information will be provided.
OptiBiotix Health plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
| || |
Walbrook PR Ltd
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
About OptiBiotix Health PLC - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human diseases, examples of which include obesity, cholesterol and lipid distribution, diabetes, and skin health.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest, appetite suppression, and skin health. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
This information is provided by RNS